| scholarly article | Q13442814 |
| P50 | author | Frank B Furnari | Q56528881 |
| P2093 | author name string | Webster K Cavenee | |
| Jill Wykosky | |||
| Paul S Mischel | |||
| Kenta Masui | |||
| Ciro Zanca | |||
| Beatrice Gini | |||
| P2860 | cites work | PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients | Q80467723 |
| RXR is an essential component of the oncogenic PML/RARA complex in vivo | Q80572862 | ||
| Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer | Q82659209 | ||
| Genetic heterogeneity and cancer drug resistance | Q83791245 | ||
| Antiangiogenic therapy: a universal chemosensitization strategy for cancer? | Q83854395 | ||
| Novel molecular targets for the therapy of renal cell carcinoma | Q84483873 | ||
| Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia | Q24299821 | ||
| Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line | Q24338329 | ||
| Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia | Q24599100 | ||
| Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus | Q24600932 | ||
| The Bcl-2 apoptotic switch in cancer development and therapy | Q24620437 | ||
| Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations | Q24632064 | ||
| Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma | Q24644727 | ||
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies | Q26829652 | ||
| Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy | Q26853604 | ||
| Novel mutant-selective EGFR kinase inhibitors against EGFR T790M | Q27658766 | ||
| MEK1 mutations confer resistance to MEK and B-RAF inhibition | Q27777362 | ||
| Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor | Q27824804 | ||
| EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 | ||
| Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. | Q27824850 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 | ||
| Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma | Q27851421 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. | Q27851589 | ||
| EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. | Q27851590 | ||
| The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers | Q27851591 | ||
| Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? | Q36163029 | ||
| Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. | Q36212896 | ||
| Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia | Q36223356 | ||
| Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer | Q36245541 | ||
| A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas | Q36319721 | ||
| Defective acidification in human breast tumor cells and implications for chemotherapy. | Q36400861 | ||
| Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance | Q36489360 | ||
| PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials | Q36510935 | ||
| Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer | Q36519458 | ||
| Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy | Q36559283 | ||
| An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance | Q36597042 | ||
| Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy | Q36661727 | ||
| Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer | Q36772562 | ||
| Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma | Q36822162 | ||
| Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. | Q36894657 | ||
| Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model | Q36982114 | ||
| mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. | Q36987718 | ||
| Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia | Q36988579 | ||
| Oncogene addiction: setting the stage for molecularly targeted cancer therapy | Q37031755 | ||
| Mechanisms of Disease: cancer stem cells--targeting the evil twin | Q37145857 | ||
| Oncogene addiction | Q37152445 | ||
| Chemotherapy for recurrent cervical cancer | Q37227843 | ||
| PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition | Q37445131 | ||
| Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial | Q37509502 | ||
| Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors | Q37539304 | ||
| Mimicking the BH3 domain to kill cancer cells | Q37566211 | ||
| Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study | Q37606591 | ||
| Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase | Q37684920 | ||
| Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies | Q37779489 | ||
| The GIST paradigm: lessons for other kinase-driven cancers | Q37815140 | ||
| Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. | Q37834921 | ||
| Novel diagnostic and therapeutic approaches to malignant glioma | Q37879020 | ||
| Cancer therapeutic agents targeting hypoxia-inducible factor-1. | Q37889311 | ||
| Liposomal drug formulations in cancer therapy: 15 years along the road | Q37943643 | ||
| Targeting MET in cancer: rationale and progress | Q37978193 | ||
| Targeting IAP proteins for therapeutic intervention in cancer | Q37980321 | ||
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 | ||
| ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. | Q27851672 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. | Q27851711 | ||
| A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer | Q27851729 | ||
| Glioma stem cells promote radioresistance by preferential activation of the DNA damage response | Q27860541 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Stem cells, cancer, and cancer stem cells | Q27860878 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| Multidrug resistance in cancer: role of ATP-dependent transporters | Q28208049 | ||
| PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma | Q28243071 | ||
| Antibody therapy of cancer | Q28262538 | ||
| Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors | Q28272463 | ||
| Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma | Q28472048 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer | Q29547558 | ||
| Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 | ||
| Cancer. Addiction to oncogenes--the Achilles heal of cancer | Q29614243 | ||
| A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations | Q29614275 | ||
| An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 | Q29614563 | ||
| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 | ||
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 | ||
| Targeting hypoxia in cancer therapy | Q29615491 | ||
| Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies | Q29615606 | ||
| The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance | Q29616511 | ||
| Targeting multidrug resistance in cancer | Q29616803 | ||
| Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer | Q29618030 | ||
| The clonal and mutational evolution spectrum of primary triple-negative breast cancers | Q29619914 | ||
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 | ||
| Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma | Q33370229 | ||
| Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma | Q33374692 | ||
| Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome | Q33389149 | ||
| Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity | Q33392920 | ||
| Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy | Q33393360 | ||
| Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease | Q33398808 | ||
| Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer | Q33400716 | ||
| Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. | Q48588707 | ||
| A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. | Q51751812 | ||
| Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. | Q52213829 | ||
| Intratumor heterogeneity: seeing the wood for the trees. | Q53097757 | ||
| Timeline: Chemotherapy and the war on cancer. | Q53313789 | ||
| CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. | Q54602410 | ||
| Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. | Q54640393 | ||
| Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy | Q57013704 | ||
| Non-small cell lung cancer | Q59565902 | ||
| Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study | Q68589708 | ||
| Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial | Q72182720 | ||
| Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell Lines | Q72561176 | ||
| Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma | Q73356015 | ||
| Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study | Q78039803 | ||
| Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial | Q80178480 | ||
| Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study | Q80336510 | ||
| Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma | Q33747609 | ||
| Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors | Q33769838 | ||
| Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. | Q33839100 | ||
| Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies | Q33925544 | ||
| Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte | Q34184706 | ||
| Targeting DNA repair proteins for cancer treatment | Q34208979 | ||
| Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial | Q34231106 | ||
| Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial | Q34263959 | ||
| Circumventing cancer drug resistance in the era of personalized medicine | Q34274940 | ||
| Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future | Q34310938 | ||
| Pharmacogenetic determinants of anti-cancer drug activity and toxicity. | Q34322733 | ||
| TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. | Q34436986 | ||
| Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim | Q34450473 | ||
| AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity | Q34511038 | ||
| Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. | Q34545921 | ||
| Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. | Q34545926 | ||
| Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. | Q34559072 | ||
| PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors | Q34606526 | ||
| Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer | Q34613161 | ||
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 | ||
| Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma | Q34655394 | ||
| PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression | Q34761941 | ||
| PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors | Q34769343 | ||
| A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. | Q35234305 | ||
| Multidrug resistance reversal agents | Q35570886 | ||
| mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling | Q35581650 | ||
| BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. | Q35588268 | ||
| Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients | Q35640624 | ||
| PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations | Q35808438 | ||
| Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors | Q35967385 | ||
| Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial | Q36097426 | ||
| Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer | Q36128435 | ||
| The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma | Q36160258 | ||
| Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge | Q37994505 | ||
| Combining immunotherapy and targeted therapies in cancer treatment | Q37995939 | ||
| From genes to drugs: targeted strategies for melanoma | Q37999967 | ||
| Pharmacogenetics of chemotherapy efficacy in breast cancer | Q38003703 | ||
| Spatial regulation of receptor tyrosine kinases in development and cancer | Q38012616 | ||
| Pushing the limits of targeted therapy in chronic myeloid leukaemia. | Q38028778 | ||
| ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. | Q38037274 | ||
| Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer | Q38042638 | ||
| The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer | Q38053414 | ||
| Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors | Q38053590 | ||
| Diffuse large B cell lymphoma: molecular targeted therapy | Q38053983 | ||
| Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. | Q39354487 | ||
| Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations | Q39385617 | ||
| Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance | Q39432471 | ||
| SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia | Q39494051 | ||
| PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors | Q39644716 | ||
| Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels | Q39760063 | ||
| Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors | Q40009900 | ||
| Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. | Q40026475 | ||
| Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation | Q40026701 | ||
| Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells | Q40124743 | ||
| A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma | Q40280414 | ||
| Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide | Q40522471 | ||
| Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. | Q40866307 | ||
| Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake | Q40896203 | ||
| Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. | Q41523907 | ||
| Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. | Q41847989 | ||
| Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells | Q41883208 | ||
| Novel therapies for aggressive B-cell lymphoma | Q42011578 | ||
| Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study | Q42673292 | ||
| Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia | Q42794744 | ||
| Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. | Q42816887 | ||
| Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma | Q43109173 | ||
| Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. | Q43279489 | ||
| A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer | Q43545482 | ||
| Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib | Q43742602 | ||
| Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study | Q43806484 | ||
| Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia | Q43962301 | ||
| A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia | Q44280538 | ||
| Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes | Q44356043 | ||
| First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial | Q44886865 | ||
| A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). | Q46239069 | ||
| Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel | Q46365805 | ||
| Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. | Q46410598 | ||
| Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study | Q46585156 | ||
| Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development | Q46681664 | ||
| Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. | Q47975546 | ||
| Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer | Q48468348 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 725-738 | |
| P577 | publication date | 2013-03-01 | |
| P1433 | published in | Carcinogenesis | Q326022 |
| P1476 | title | A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments | |
| P478 | volume | 34 |
| Q90419746 | A Humanized Yeast Phenomic Model of Deoxycytidine Kinase to Predict Genetic Buffering of Nucleoside Analog Cytotoxicity |
| Q42276844 | A systematic analysis of FDA-approved anticancer drugs |
| Q27027458 | Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins |
| Q54940867 | Adherence to Oral Anticancer Medications: Evolving Interprofessional Roles and Pharmacist Workforce Considerations. |
| Q31155008 | Advantages of an optical nanosensor system for the mechanistic analysis of a novel topoisomerase I targeting drug: a case study |
| Q36372931 | Cancer cell-selective killing polymer/copper combination. |
| Q95360035 | Clinical study of ultrasound and microbubbles for enhancing chemotherapeutic sensitivity of malignant tumors in digestive system |
| Q34478394 | Co-encapsulation of Doxorubicin with galactoxyloglucan nanoparticles for intracellular tumor-targeted delivery in murine ascites and solid tumors. |
| Q90576377 | Codependency of Metabolism and Epigenetics Drives Cancer Progression: A Review |
| Q41915916 | Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations. |
| Q92520508 | Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model |
| Q39263090 | Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation. |
| Q60051003 | Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation |
| Q38788869 | Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells |
| Q38222758 | Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment |
| Q90316105 | KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations |
| Q103825970 | Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects |
| Q92516722 | Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice |
| Q34008793 | Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years |
| Q92286519 | Recombinant human PRG4 (rhPRG4) suppresses breast cancer cell invasion by inhibiting TGFβ-Hyaluronan-CD44 signalling pathway |
| Q39309007 | Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target. |
| Q42109090 | Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy. |
| Q90641451 | The great escape: tumour cell plasticity in resistance to targeted therapy |
| Q42559043 | mTORC2 dictates Warburg effect and drug resistance |
| Q37014165 | mda-7/IL-24 Induces Cell Death in Neuroblastoma through a Novel Mechanism Involving AIF and ATM. |
Search more.